Skip to main content
. 2022 Oct 22;14(21):5173. doi: 10.3390/cancers14215173

Figure 3.

Figure 3

Overall survival from initiation of cabozantinib therapy in patients with advanced hepatocellular carcinoma who progressed initially on immunotherapy.